Thrombectomy in special populations: report of the Society of NeuroInterventional Surgery Standards and Guidelines Committee.
Fawaz Al-MuftiClemens M SchirmerRobert M StarkeNeeraj ChaudharyReade De LeacyStavropoula I TjoumakarisNeil HaranhalliIsaac Josh AbecassisKrishna AmuluruKetan R BulsaraSteven W Hettsnull nullPublished in: Journal of neurointerventional surgery (2021)
MT can be effective for the treatment of ELVO in ischemic stroke for patients over age 80 years and under age 18 years, thrombocytopenic patients, pregnant patients, and patients with endocarditis. While outcomes are worse compared to younger patients and those with normal platelet counts (respectively), there is still a benefit in the elderly (in both mRS and mortality). Data are very limited for patients with collagen vascular diseases; although diagnostic cerebral angiography carries increased risks, MT may be appropriate in carefully selected patients in whom untreated ELVO would likely result in disabling or fatal outcome.
Keyphrases
- end stage renal disease
- newly diagnosed
- prognostic factors
- risk assessment
- computed tomography
- cardiovascular disease
- type diabetes
- coronary artery disease
- risk factors
- atrial fibrillation
- acute coronary syndrome
- brain injury
- adipose tissue
- skeletal muscle
- climate change
- human health
- middle aged
- cardiovascular events
- combination therapy
- clinical practice
- wound healing